INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

April 24, 2023

Biotechnology

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

January 3, 2025
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

January 3, 2025
BrainStorm Issues 2024 Letter to Shareholders

December 30, 2024
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

December 20, 2024